HTR1A and schizophrenia: This hypothesis is consistent with the preclinical finding that CBD attenuates cognitive impairments in a schizophrenia-like animal mode and that these effects can be blocked by a 5-HT1A receptor antagonist but not by CB1 and CB2 receptor antagonists (Rodrigues da Silva et al., 2020).